Intellectual property rights in space based biotech inventions

Introduction

Space-based biotechnology involves scientific research and technological innovation conducted in outer space or using space-related infrastructure. It includes experiments involving microorganisms, plant cells, human tissues, protein crystallisation, genetic engineering, biomanufacturing and the development of medicines under microgravity conditions. Such inventions may produce valuable discoveries with applications in healthcare, agriculture, pharmaceuticals and industrial biotechnology.

Intellectual property rights (IPR) play an important role in protecting these inventions. However, space-based biotechnology creates complex legal questions because research may involve several countries, international space stations, private companies and government agencies. Determining ownership, territorial jurisdiction and the enforcement of patent rights becomes particularly challenging when an invention is developed beyond Earth.

Legal framework governing space-based biotechnology

The protection of space-based biotech inventions is governed by national intellectual property laws and international space treaties.

The Outer Space Treaty, 1967, establishes the fundamental principles governing activities in outer space. Article I provides that outer space shall be freely explored and used by all states. Article II prohibits national appropriation of outer space. Article VI makes states internationally responsible for their national space activities, including activities conducted by private entities.

The Patent Cooperation Treaty, 1970 (PCT) facilitates international patent applications by allowing inventors to seek patent protection in multiple countries through a common application procedure. However, it does not create a single worldwide patent. Patent protection ultimately depends on the laws of individual countries.

The TRIPS Agreement, 1994, establishes minimum international standards for intellectual property protection. Article 27 provides that patents shall generally be available for inventions in all fields of technology, subject to specified exceptions.

Patentability of space-based biotech inventions

Space-based biotechnology inventions may qualify for patent protection when they satisfy the applicable requirements of novelty, inventive step and industrial applicability.

Examples include:

New pharmaceutical compounds developed through microgravity experiments.

Improved methods of protein crystallisation.

Genetically modified microorganisms designed for space-based manufacturing.

Bioreactors developed for producing biological materials in spacecraft.

New processes for growing plant cells under reduced-gravity conditions.

Under Section 2(1)(j) of the Indian Patents Act, 1970, an invention must involve a new product or process, an inventive step and industrial applicability.

However, Section 3 contains exclusions from patentability. For example, naturally occurring biological materials may not qualify merely because they have been discovered. Section 3(c) excludes the mere discovery of a scientific principle or naturally occurring substance, while Section 3(j) excludes plants and animals, including seeds, varieties and species, and essentially biological processes for their production or propagation.

Therefore, a space-based discovery does not automatically become patentable. It must satisfy the applicable statutory requirements.

Ownership and jurisdictional challenges

One of the major challenges concerns determining who owns an invention created in outer space. A biotechnology experiment may involve astronauts, university researchers, private corporations and government-funded institutions from different countries.

The International Space Station Intergovernmental Agreement, 1998 (IGA) provides an important framework for addressing intellectual property rights arising from activities aboard the International Space Station. Under Article 21, each partner exercises jurisdiction and control over the elements it registers and over its personnel in the circumstances specified by the Agreement. Intellectual property rights are generally determined according to the national law applicable to the relevant partner.

This framework helps determine which national patent law may apply to inventions created aboard the ISS. However, it does not eliminate every ownership dispute, particularly where researchers from multiple jurisdictions contribute to the same invention.

Important case laws

1. Diamond v. Chakrabarty (1980), United States Supreme Court

The US Supreme Court held that a genetically engineered microorganism could be patentable because it was a human-made invention rather than merely a product of nature. The judgment is relevant to space biotechnology because microorganisms engineered for pharmaceutical production or waste management in spacecraft may qualify for patent protection if statutory requirements are satisfied.

2. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013), United States Supreme Court

The Court held that naturally occurring DNA is not patentable merely because it has been isolated, although synthetically created complementary DNA may be patentable in appropriate circumstances. This distinction is relevant when space-based biological research identifies genetic material or develops engineered genetic products.

3. Novartis AG v. Union of India (2013), Supreme Court of India

The Supreme Court interpreted Section 3(d) of the Patents Act and rejected patent protection for a modified pharmaceutical substance that did not demonstrate the required enhancement of therapeutic efficacy. The decision is important for space-developed medicines because pharmaceutical inventions must satisfy India's patentability standards even when the underlying research is conducted in outer space.

4. Harvard College v. Canada (Commissioner of Patents) (2002), Supreme Court of Canada

The Court considered whether a genetically modified higher life form could be patented under Canadian patent law and concluded that it was not patentable under the relevant statutory framework. The decision demonstrates that national approaches to biotechnology patentability may differ.

These decisions are relevant by analogy; none directly determines ownership of an invention created aboard a spacecraft.

Confidentiality and commercial exploitation

Space-based biotechnology research may involve confidential experimental data, proprietary biological processes and commercially valuable research materials. Trade secret protection can safeguard information that is not publicly disclosed and is subject to reasonable confidentiality measures.

Research agreements should clearly establish:

Ownership of inventions developed jointly.

Rights to publish scientific results.

Confidentiality obligations.

Patent application responsibilities and costs.

Licensing and commercialisation arrangements.

Rights relating to biological samples and research data.

Such agreements are particularly important where public research institutions and private space companies collaborate.

Conclusion

Intellectual property rights in space-based biotechnology require coordination between patent law, international space law and contractual arrangements. The Outer Space Treaty and the International Space Station framework provide important jurisdictional principles, while national patent laws determine whether particular inventions qualify for protection. As commercial biotechnology activities in space expand, clearer international standards will be necessary to address ownership, patent enforcement, licensing and equitable access to scientific innovations.